Concepedia

Publication | Open Access

A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

DOIFull Paper Access

150

Citations

23

References

2004

Year

Alan Sandler, Michael A. Gordon, Dinesh P. de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Ajai K. Chaudhary, Karen Fife, Linda A. Battiato, Christopher Sweeney,
Clinical Cancer Research

Abstract

Zosuquidar can be safely coadministered with doxorubicin using a 48 h i.v. dosing schedule.

References

YearCitations

Page 1